Psilocybin microdosing is often promoted as a creativity hack. If you’ve spent any time in biohacking or nootropics communities, you’ve probably heard the claim: take tiny doses of psilocybin and you’ll think more creatively.
For years, much of that idea has been based on personal reports and anecdotal experiences. But a recent analysis published in Neuropharmacology takes a far more rigorous look at psilocybin microdosing and creativity.
Researchers led by Leiden University combined data from three double-blind, placebo-controlled longitudinal trials involving 171 participants. The result offers a more nuanced picture than either the hype or a simple “it doesn’t work” conclusion.
Some links in this article are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. See our affiliate disclaimer.
What the Researchers Actually Tested
The researchers weren’t simply asking participants whether they felt more creative. Instead, the studies examined two different aspects of creative thinking:
- Divergent thinking: generating multiple possible ideas or solutions to an open-ended problem. One of the measures was the Alternative Uses Task, in which participants list unusual uses for an everyday object.
- Convergent thinking: combining information or associations to arrive at a single correct answer. The studies used tasks such as the Remote Associates Test and the Picture Concept Task.
After running three separate experiments, the team pooled the individual-level data into a single mega-analysis of 171 participants. That approach gave them more statistical power than any one experiment could provide on its own.
Psilocybin Microdosing and Creativity: The Results
Here’s where the findings get interesting. The analysis did not show a general improvement in creativity.
Psilocybin microdosing did not reliably increase the number of ideas participants generated, improve flexibility in their responses, or improve performance on convergent thinking tasks.
But one measure stood out: the originality ratio, which is the proportion of original responses relative to the total number of responses produced.
In simpler terms, participants didn’t produce more ideas. Instead, a higher share of the ideas they did generate were rated as original — an improvement in the quality of divergent thinking rather than the quantity.
There’s an important catch. According to the published abstract, the originality effect appeared only when the researchers accounted for relative dosage — the dose adjusted for each participant’s body weight. The finding also held after controlling for participants’ guesses about whether they had received psilocybin or placebo.
So the study does not show that psilocybin microdosing makes people broadly more creative. It suggests that, under the conditions tested, it may affect one specific aspect of divergent thinking.
Why the Findings Are More Nuanced Than the Hype
The popular narrative often treats creativity as a single ability that can simply be switched on. These results don’t support that view.
Creativity involves multiple cognitive processes. Someone might become better at generating unusual associations without becoming better at solving problems that require a single logical answer. That’s essentially what this research found: a signal in one aspect of divergent thinking, and no improvement in several other measures.
Even that signal needs cautious interpretation. The three experiments did not produce identical results, and pooling studies increases statistical power without turning a limited finding into proof of a broad cognitive benefit. The researchers themselves describe the effects as specific and limited.
What About the Placebo Effect?
Expectations are one of the biggest challenges in psilocybin microdosing research. If someone believes they’ve taken psilocybin, that belief alone can shape how they perceive their performance.
That’s why the researchers checked whether participants’ guesses about their condition could explain the results. The originality-ratio finding remained after controlling for dose-guessing and demographic factors. The authors still stress that placebo effects and previous psychedelic experience must be controlled carefully in future studies — which is exactly why double-blind, placebo-controlled designs matter so much in this field.
What the Study Does — and Doesn’t — Tell Us
It’s tempting to turn a result like this into a simple headline: “Psilocybin microdosing makes you more creative.” But that’s not what the study demonstrated.
A more accurate summary would be:
In a pooled analysis of three double-blind, placebo-controlled trials involving 171 participants, psilocybin microdosing was associated with a higher originality ratio on divergent-thinking tasks, while researchers found no improvement in other divergent-thinking measures or in convergent thinking.
That’s a much narrower claim — and a much more useful one. The study measured performance on specific lab tasks. It did not establish that psilocybin microdosing improves creativity in everyday work, art, or business, or that it’s an effective general-purpose cognitive enhancement strategy.
What Are the Limitations?
- Narrow effect: the finding was specific to one measure of divergent thinking, not a broad improvement across creativity measures.
- Dose-dependent result: the originality effect only appeared when dose was adjusted for body weight.
- Inconsistent experiments: the three trials used different designs and protocols, and not all of them produced the same results on their own.
- Lab vs. real life: listing unusual uses for an object in an experiment doesn’t tell us whether someone will write a better novel, design a better campaign, or solve a complex business problem.
- Expectation effects: placebo effects and prior psychedelic experience remain important variables when interpreting psilocybin microdosing research.
So the most interesting takeaway isn’t that psilocybin has been “proven” to boost creativity. It’s that researchers are beginning to identify which specific components of creative thinking might change, and which don’t.
Exploring Non-Psychedelic Nootropic Options
The findings above are interesting from a research perspective, but they don’t establish psilocybin microdosing as a cognitive-enhancement strategy — and psilocybin remains illegal in most places.
If your real goal is sharper everyday focus, memory, and mental clarity, legal nootropics take a completely different approach. To be clear, they are not substitutes for psilocybin, and nothing in this study suggests they produce the same effects. Their evidence has to be judged on its own.
If you’re new to the category, start with our guide to nootropics for beginners, or see our tips on how to boost brainpower naturally.
One Formula to Compare: Mind Lab Pro
Mind Lab Pro is a stimulant-free, multi-ingredient nootropic built around everyday cognitive performance. It combines 11 ingredients, including Citicoline, Bacopa Monnieri, Lion’s Mane, and L-Theanine, in a transparent formula with no proprietary blends.
For a full breakdown of the formula, results, and price, read our Mind Lab Pro review.
→ Check the current price of Mind Lab Pro
Legal and Safety Considerations
Psilocybin is a controlled substance in most countries, and its legal status varies widely by jurisdiction.
The research discussed here was conducted under controlled experimental conditions, with known doses and medical screening. That is very different from unsupervised use, where the identity, strength, and purity of a substance may be unknown.
Nothing in this article is a recommendation to use psilocybin or a guide to consuming it. The value of this research lies in what it reveals about cognition under controlled conditions — not in offering a protocol for self-experimentation.
FAQ
Does psilocybin microdosing actually make you more creative?
Not in a broad sense. A pooled analysis of three double-blind, placebo-controlled trials with 171 participants found an increase in the originality ratio — the share of original responses among all responses — but no improvement in other divergent-thinking measures or in convergent thinking.
What is the originality ratio?
It’s the proportion of responses rated as original relative to the total number of responses. It measures the quality of ideas rather than simply how many ideas someone generates.
Did the study show that psilocybin improves problem-solving?
No. The researchers found no effect of psilocybin microdosing on convergent thinking, which involves integrating information to reach a single correct solution.
Was this a placebo-controlled study?
Yes. It combined data from three double-blind, placebo-controlled longitudinal trials and also tested whether participants’ guesses about their condition influenced the results.
Does this prove psilocybin microdosing improves creativity in everyday life?
No. The study measured specific aspects of creative thinking in a lab setting. Whether the effect translates into meaningful real-world creative gains remains an open question.
Are there legal alternatives for cognitive performance?
Many legal nootropic products are marketed for focus and mental clarity, but they should not be considered equivalent to psilocybin or assumed to produce the same effects. The evidence for each ingredient needs to be evaluated separately.
The Bottom Line
The newest evidence doesn’t support the idea that psilocybin microdosing simply makes people “more creative.” Instead, three double-blind, placebo-controlled trials with 171 participants found something more specific: a higher originality ratio, with no improvement on other divergent-thinking measures or on convergent thinking.
If psychedelics influence creative cognition at very low doses at all, the effect appears to be subtle and specific rather than a broad creative boost — and that’s exactly the kind of question better controlled research can help answer.
Source
Prochazkova, L., Marschall, J., van Elk, M., Rifkin, B. D., Schon, N. R., Fiacchino, D., Fejer, G., Kuchar, M., & Hommel, B. (2026). Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials. Neuropharmacology, 284, 110732. https://doi.org/10.1016/j.neuropharm.2025.110732